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a B S T r a c T
The world is now entering its 9th month of combat against a pandemic of deadly pneumonia. Started out from china in 
december 2019, the disease has been declared as caused by infection with a so far unknown rna coronavirus of the 
respiratory family, then named severe acute respiratory syndrome coronavirus SarS-cov-2. in the absence of a vaccine, 
and with scientists still struggling for an effective therapy, cOvid-19 (the SarS-dependent syndrome) carries up to 
now, a death toll of more than 590,000 (July 18,2020) undermining jobs and finance of contemporary society in all conti-
nents. Social distancing, the only measure hitherto shown to restrain virus spread, has been progressively loosened from 
May 2020 in some countries, leaving us in the fear of repeat attacks from the unchecked virus. We discuss the problem 
and propose to tentatively boost the antivirus cell machinery by using lab-made viral mimics to engage cell receptors.
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Clinical facts and epidemiologic figures
at the end of december 2019, an unusual concentration of cases of severe pneumo-
nia in the chinese region of Hubei (and Wu-
han as the main city) aroused investigators’ 
and physicians’ attention towards the possible 
breaking-in of a novel pathogen.1 Soon, rele-
vant cases invaded mainland china and several 
countries abroad, leading international Health 
authorities to classify it as a pandemic a few 
weeks following the initial claims.2 as of today 
(July 18, 2020), media information is reckon-
ing worldwide figures of:1)14,104,033, and 
597,36; 2) 2.062,189 and 77,851; 3) 3,650,962 
and 161,163 respectively, of infected people 
and fatalities, worldwide, in Brazil, and in the 
USa.3 Worst hit areas localize to West-central 
europe and the USa. Social distancing, the 
only form of policy commonly activated in all 
countries, is now yielding mixed results prob-
ably as a function of timing of its implementa-
tion and people adherence. italy, France, Spain 
and Germany which were involved first, seem 
now to begin the plateau phase hopefully her-
alding phases 2 then 3 of descent and resolu-
tion; in contrast, in the USa, number of cases is 
still on the rise. in the china province of Hubei, 
where possibly everything had begun (probably 
earlier than initially believed), data are vari-
able: whilst contagion and disease figures seem 
to decay in the initial infection sparkle of Hubei, 
so-called return infections are threatening to in-
vert the trend. recently noted infection spots at 
the russian border are now setting up a russian 
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significant proportion of so-called healthy car-
riers are suspected to be infectious. according 
to chinese data, approximately 82% of cO-
vid-19 patients may present with mild symp-
toms and prompt recovery; in a series of severe 
hospitalized patients in Guangdong (china), 
26% recovered, and 13% died. in other series, 
mortality in the intensive care unit (icU) was 
26%.10 Study of patient’s characteristics may 
yield prognostic clues. elderly male subjects 
with co-morbidities have been found to be the 
most susceptible. Frailty, as in case of diabetes, 
hypertension, and stenotic cardiomyopathy can 
play a negative role,10, 11 and sexual hormones 
and their age-driven fluctuations may also 
contribute to disease severity. Studies of influ-
enza vaccination have suggested that women 
are more responsive to vaccination than men, 
insofar by reporting more local and systemic 
reactions to flu vaccine than men, when ques-
tioned in surveys.12 This is due to a clear im-
mune suppressive effect of male testosterone 
witnessed by a negative post-vaccination anti-
body regulation in males with regular male hor-
mone secretion (of great interest for the search 
for prognostic markers of the cOvid-19 syn-
drome).13 The opposite is clearly true: elderly 
males with diminished testosterone levels have 
higher levels of circulating proinflammatory 
cytokines.14 Such differences are also mirrored 
by clinical evidence: epidemiological data for 
2004-2010 flu epidemics in Hong-Kong showed 
a higher resort to hospitalization for men than 
women.15 Finally, of top relevance is the find-
ing of a heightened susceptibility for fatal com-
plications in middle-aged men hospitalized for 
acute respiratory disorders,16 hence confirming 
an important role played by patient variability. 
Regarding the modalities of infection, first-hand 
experience indicates that the health-care staff is 
more often hit by a severest disease grade, im-
plying that a serious causative role is played by 
the higher viral loads encountered by the work-
ers in the hospital setting.17
Underlying physiopathological circuits mir-
rored in specific clinical pictures
Many infectious (like cOvid-19) and non-
infectious conditions (for example, autoimmu-
now facing a new lockdown, owing to heavy vi-
ral return.
Worldwide data and trends gathered in the 
past few months show that the viral infection is 
not dependent on season or race, and urgently 
warrants antiviral solutions.
The virus
The recognized agent of the syndrome (as de-
scribed below) belongs to the coronaviridae 
family (now officially filed as severe acute re-
spiratory syndrome coronavirus-cov-2 [SarS-
cov-2]); it is a single-stranded/positive stranded 
rna entity. The genome is 26,000 to 32,000 
bases long and is organized and wrapped into 
a nucleocapsid, making this virus the largest 
among the known rna viruses. Two thirds of 
the sequence encode for the functional proteins 
of transcriptase/helicase; the remaining 1/3 re-
lates to the transcription of 4 structural proteins: 
spike; envelope; membrane and nucleocapsid. 
The mature viral particles have a dimension of 
70-90 nm.4 among the many host species that 
can potentially be infected by coronaviruses, 
birds and humans are at the top of the list. in 
such categories SarS-cov-2 may induce an ar-
ray of disturbances ranging from mild-to-severe 
respiratory disease, to gastrointestinal malfunc-
tion.5-8
Clinical manifestations
SarS-cov-2-related infection may be confus-
ing and deceptive at presentation and at resolu-
tion. By and large, the disease (named cOvid 
19) development may include two phases.9 in 
the initial phase, when the viral effects pre-
dominate, respiratory signs/symptoms are seen; 
later on, the virus’ role may become less promi-
nent and inflammation leading the well-known 
cytokine storm prevail. To this regard, treat-
ment should mostly rely on antivirals in initial 
phases while immune modulation with steroids 
and/or anti-inflammatory monoclonals will be 
mostly indicated for the second phase. among 
the coronaviridae, this virus seems to be the 
most apt to spill from the upper airways, thus 
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vide the available therapeutic options for cO-
vid-19. This document, entitled “Treatment 
Guidelines for cOvid-19” was released april 
21, 2020 and is synthesized below.27
• There are no sufficient data to advise or dis-
courage the use of the following measures:
• chloroquine (recently deleted because of 
conflicting results);
• remdesivir (on May 1st, the regulatory 
authority has reckoned that, despite the absence 
of a formal proof of effectiveness, remdesivir 
[Gilead Sciences, Foster city, ca, USa] seems 
to shorten disease course in hospital; hence, a 
“emergency use authorization” has been issued 
under this specific indication;
• convalescent plasma;
• interleukin (iL)-1 or iL-6 inhibitors;
• interferons or Janus Kinase inhibitors 
may be allowed only in clinical trials.
• concomitant medications:
• angiotensin-converting enzyme (ace) 
inhibitors are discouraged outside a trial context;
• systemic corticosteroids are discouraged 
in mechanically ventilated subjects with or with-
out acute respiratory distress syndrome (ardS). 
These medications should not be routinely pre-
scribed to patients affected by SarS-cov-2 in 
intensive care Unit (icU);
• pre-existing prescriptions of oral/inhaled 
corticosteroids should be continued for the usual 
indications. Betamethasone and dexamethasone 
(crossing the placenta) should be prescribed only 
for strict fetal benefit; the other steroids (not 
passing the placenta) may not be restricted. The 
offering of antenatal steroids is not encouraged 
and will be subject to the guidelines of the rel-
evant american associations;
• statins or non-steroidal anti-inflammatory 
drug (nSaids) should be continued if prescribed 
previously for comorbid condition;
• a positive or negative SarS-cov-2 con-
dition should not influence choice of an anti-
pyretic therapy (nSaid or paracetamol);
• an excessive prevalence of severe venous 
thromboembolic accidents has been reported in 
a number of patients affected by SarS-cov-2 
in the icU.18 Whether this new observation will 
entail modification of current heparin trials will 
have to be decided.
nity), thanks to their altered inflammatory cir-
cuits, can impact on the coagulation pathways. 
Specifically, the COVID-19 syndrome has been 
described in conjunction with severe veno-oc-
clusive disease.18 Most recently, and particularly 
alarming for pediatricians, is the description of 
an unexpected prevalence of Kawasaki disease 
(inflammatory thrombotic disease of cardiac ves-
sels) involving infants from a restricted area of 
Lombardy (italy).19 To this regard, current break-
ing news have revealed that cOvid-19-related 
veno-occlusive disease may cause severe limb 
ischemia, requiring urgent amputation.20
Uncommon clinical presentation
Up to 50% of all infections by SarS-cov-2 may 
present exclusively with gastrointestinal symp-
toms, as their gut microbiota might have been 
upset by interferon (iFn) released during the vi-
ral lung attack.21 Furthermore, gut permeability, 
that plays a crucial role in health as well as in 
several diseases,22 could be altered by this infec-
tion. This special cOvid-19 subset may run a 
prolonged disease course, with diarrhea and ab-
dominal pain and SarS-cov-2 viral elements 
found in the feces.23
Real time notes
The doctor’s Guide Bulletin is reporting on eu-
ropean cases of a non-better characterized Pe-
diatric Inflammatory Multi-System Syndrome, 
marked by fever, abdominal pain, and cardiac 
involvement. clinically, the picture may fall 
half-way between Kawasaki disease and toxic 
shock syndrome. a temporal association be-
tween this syndrome and SarS-cov-2 must not 
be neglected, but no official position has been 
taken until further data come to the regulatory 
authority.24
Treatment
data reported hitherto suggest that SarS-cov-
2-induced infection should be regarded more 
than a “tenacious flu,” due to its ability to induce 
severe respiratory illnesses leading to death in 
the most susceptible individuals.25, 26
Thus, the USa national institutes of Health 
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Therapy options
Usual corticosteroids (intravenous methylpred-
nisolone 1 mg/Kg) can control the inflamma-
tion cascade in these patients, from initial tissue 
infiltration to full ARDS. Timely choices from 
experienced clinicians are of course required, as 
excessive or too early doses can be detrimental if 
fostering viral replication. The variegated steroid 
toxicity must equally be monitored. TNF block-
ers can be anticipated to be effective, but specific 
experience with their use is null or limited.29, 30
according to the available literature, conva-
lescent plasma has been infused to patients af-
fected by SarS-cov-2 in some cases.31 The 
reportedly good results are in keeping with the 
simple but robust fact that convalescent plasma 
must necessarily contain the relevant healing an-
tibody. Given the cost-effectiveness and relative 
safety, the pharmacological profile of COVID-
19-convalescent plasma should be regarded more 
closely.32 The plasma of patients discharged after 
recovery from cOvid-19 should be bio-banked 
for further studies.
The need to protect large masses of people in-
fected or re-infected by respiratory viruses in-
cluding SARS-CoV-2
Historical background
at the turning of the 9th month of the cOvid-19 
pandemic, most countries around the world are 
facing the challenge of gradually loosening the 
rules of social distancing, as a prerequisite to 
slowly return to a “normal” life.26 This might be 
risky in the absence of a vaccine and of any ap-
proved anti-SarS-cov-2 drug. a reactivation of 
the pandemic during the downgrading of the re-
striction measures would have mass psychologic 
and medical consequences with a difficult-to-see 
outlook.33 a possible response to the challenge 
may include: harnessing the innate immune sys-
tem to non-specifically respond to viral infection, 
creating a continuous antivirus shield. This strat-
egy would be successful despite any viral muta-
tion.34 To succinctly but precisely illustrate the 
essential steps, the following is needed: 1) using 
its cell effectors natural killer (NK) and natural 
t-killer cells (NKT) bearing pathogen recogni-
tion receptors (Prr), the innate immune system 
Most recently, an updated reappraisal of the 
treatments and strategies for the syndrome of 
cOvid-19 has been published.28
Two issues that relevantly impact on the 
management of COVID-19 syndrome
The cytokine storm (or syndrome)
The term “cytokine storm” was first used in 
1993, alluding to a hitherto undescribed pic-
ture of uncontrolled immune activation, usu-
ally following cluster of differentiation (cd)3 
maneuvers to modulate transplant and graft-
versus-host disease. The syndrome included 
clinical features of immune activation (fever 
and generalized malaise), as well as accumu-
lation of proinflammatory cytokines. The study 
on severe acute respiratory syndrome related 
to SarS-cov in mice has been seminal in this 
respect. The rapid replication of SarS-cov in 
BaLB/c mice induced the delayed release of 
IFN-α/β, which was accompanied by the influx 
of many pathogenic inflammatory mononu-
clear macrophages. These cells were activated 
through the IFN-α/β receptors on their surface 
and produce more monocyte chemoattractants 
(such as ccL2, ccL7, and ccL12), resulting 
in further accumulation of mononuclear mac-
rophages and production of elevated levels of 
proinflammatory cytokines (tumor necrosis 
factor [TNF]), IL-6, IL1-β, and inducible nitric 
oxide synthase), thereby increasing the disease 
severity. Interestingly, depleting the inflamma-
tory cytokine TnF, protected mice from the 
fatal SARS-CoV infection. IFN-α/β or mono-
nuclear macrophage-derived proinflammatory 
cytokines also induced the apoptosis of T cells, 
which further hindered viral clearance. another 
consequence of rapid viral replication and vig-
orous proinflammatory cytokine/chemokine 
response is the induction of apoptosis in lung 
epithelial and endothelial cells. indeed, apop-
tosis of alveolar and epithelial cells, completed 
by vascular and generalized organ damage can 
form the basis for the genesis of the ardS, a 
leading cause of death in these SarS-cov-2-
infected patients. Thus, treatment of this cyto-
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iL-4 and iL-5 in lung tissue. Given prophylacti-
cally, poly(i:c) abolished the replicative compe-
tence of many viruses, including influenza, her-
pes simplex, and yellow fever.
For clinical use, poly(i:c) may be one of the 
most appropriate agents to generate stable ma-
ture dendritic cells (dcs). These mature dcs 
might generate effective immune responses in 
vivo after injection, as they retain the ability to 
secrete bioactive iL-12 after cd40 ligation.
Toxicity
in preliminary studies, poly(i:c) and deriva-
tives have consistently shown varying degrees 
of intrinsic toxicity, a major obstacle hindering 
their release as regular drugs. TLr3 activation 
was used to detect toxicity signs. essentially, 
two toxicity patterns were described in mice. re-
peated intranasal administrations were followed 
by lung inflammation including edema and cell 
infiltration; several administration routes in auto-
immunity prone animals mainly resulted in pan-
creatitis or worsening of nephritis.38, 39 attempts 
to characterize the consequence of diversifying 
routes of administration yielded conflicting re-
sults depending on the animal species. attempts 
were made using lower doses in adjuvant de-
signs, masquerading poly IC under liposomes 
shells, co-administering steroids, but albeit 
promising these yielded mixed results. Specific 
thiolation of the cytosine residues on the rna 
chain has also attracted attention.40
Where are we now?
Today’s reappraisals indicate the following. Poly-
icLc is now dispensed as a regular drug under 
the registered label HiLTOnOL® (Oncovir inc., 
Washington dc, va, USa). HiLTOnOL® is 
now employed in three investigational settings: 
1) as an adjuvant in antitumor therapeutics; 2) as 
a TLr 3 agonists in viral diseases; 3) as a drug 
included in antihuman immunodeficiency virus 
(Hiv) trials. in the latter ones, it is at the i/ii 
dose-finding levels.
a work published in 201741 summarizes the 
state of the art reached with the experimental use 
of poly(i:c) against respiratory viruses in pre-
recognizes and responds to specific ligands on 
the pathogen surface termed pathogen associ-
ated molecular patterns (PaMPs). This is then 
followed by release of cytokines to mount an ef-
fective immune response. in humans, the invader 
antigens are recognized by detectors Toll-like re-
ceptors (TLr) belonging to the Prr family. all 
TLr basically include a membrane leucine-rich 
motif (antigen-sensing) and an effector cytoplas-
mic tail that conveys proinflammatory signals to 
the cell machinery. antigen categories recognize 
specific TLR. The double-strand RNA of the re-
spiratory viruses like SarS-cov-2 is recognized 
by TLr-3.35 Thus, TLr3 is the cell sensor that 
has to be targeted if projecting maneuvers to 
arouse a response to an experimental or sponta-
neous SarS-cov-2 attack. Located at the cell 
membrane of nasal, alveolar, bronchial epithelial 
cells, and ready to respond to any sub-cellularly 
localized rna, TLr3 constitutes a prompt non-
specific antiviral weapon. Its ligands are gen-
erally named TLr3 agonists. at this point, we 
should ask whether the coronaviridae can be in-
cluded in this strategy, which double strain (ds)
rna mimicry molecules are best candidates as 
the drugs for this project, and how feasible is all 
this in humans.
The virus and its candidacy for prevention with 
synthetic dsRNAs
SarS-cov-2 can be expected to engage regular 
forms of TLr3. There is an emphasis in the lit-
erature on the Sars-cov-2 propensity to induce 
multiple reactivations with time, probably due 
to a high mutation frequency.36 in T-cell im-
munodeficient hosts, this virus tends to provoke 
cytokine storms, rendering treatment even more 
demanding.
Various TL3-agonists exhibit the structure of 
dsRNAs
Synthetic dsrnas, at least 40-50 base pairs in 
length, including polyinosinic:polycytidylic acid 
(poly(i:c)) alone or stabilized with poly-L-lysine 
and carboxymethyl cellulose (Poly-icLc) and 
polyadenosinic-polyuridylic acid (poly [aU]) 
have been used as molecular mimics for viral 
dsrna.37 Such compounds have been shown 
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virals are complex and expensive, and subject to 
virus mutation. Looking at the frustration of peo-
ple trying to use an escalator or entering a shop, 
yet struggling to maintain safety distances, we 
thought it worth inaugurating a strategy to for-
get about the virus and concentrate on shielding 
every individual: if it is raining and you cannot 
push the clouds away, you can still cover peo-
ple’s shoulders with a raincoat, taking them to 
a sheltered place: clearly a periphrasis for “keep 
momentarily safe until a vaccine comes out.”45 
The recent announcement (august 11, 2020) of 
the availability of a russian vaccine has raised 
perplexities due to the lack of large trials aiming 
to test vaccine safety.46
We chose to concentrate on poly(i:c) as a 
means to “taxi” virus-exposed people to a virus-
free shelter, acknowledging that this is not the 
only way. Of course, we have no conflict of inter-
est whatsoever, we are simply committed to the 
idea. neither are we planning to press regulatory 
authority to release an emergency use authoriza-
tion (eUa). On the other hand, nine months after 
the pandemic outbreak, there is a need for a fac-
tual (though temporary) action, to restore some 
ease of mind for people battered by unmet anxi-
ety and scare.
Current virus-host co-existence in the absence of 
a strategy based on poly:IC
The long delay in the implementation of an an-
tivirus strategy using TLr3 agonists, has led 
SarS-cov-2 infection to become a pandemic. 
SarS-cov-2 will integrate in our society, es-
tablishing a mutual co-existence balance with 
mild diseases, that unfortunately will reactivate 
in permissive conditions, with erratic re-appear-
ance of symptoms. Spontaneous down-grading 
of virus power coupled with our improved skills 
to control disease manifestations will hopefully 
achieve an acceptable co-existence. if the virus 
elude control, there will be the risk of renovat-
ing the core presentation with cytokine storm 
and lung disease requiring admission to inten-
sive care. at that point, the threat of massive 
admissions with collapse of resuscitation facili-
ties, will renovate the need for social distancing 
culminating in the well-known lock-down and 
its unavoided implications.26 certain negative 
clinical studies. Briefly, pre-emptive intranasal 
doses from 0.25 to 5 mg/Kg/day significantly 
protected mice from lethal units of SarS-cov; 
interestingly, poly(i:c) exerted 100% protection 
if administered up to 8-hours postviral expo-
sure. Literally citing the authors: “host-targeted 
therapeutics, such as HiLTOnOL®, that activate 
innate immunity and provide immediate broad 
spectrum resistance, could fill the gap in protec-
tion by allowing time for more specific vaccina-
tion strategies to take effect, and could thus be-
come an important element of the rapid response 
to a bioterror attack or pandemic outbreak. The 
demonstrated clinical safety, its immediate in-
duction of an innate immune persistent broad 
spectrum antiviral state, its relatively low cost, 
its storage stability and relative ease of use, make 
it a potentially very valuable agent for contain-
ment of epidemics caused by respiratory patho-
gens.”41
Conclusions
at the beginning of this year, an unexpected 
combat began (and there are no clues on when 
it will end) between mankind (ourselves) and a 
supposedly unknown respiratory virus labelled 
as SarS-cov-2. Both contestants do manifest a 
few intriguing yet worrying features. The virus 
is reported to easily grow in the upper airways, 
hence exhaled from breath droplets for a maxi-
mum contagion; serology or molecular screen-
ing have often failed to confirm eradication; thus, 
this pathogen can undermine the social, produc-
tive, and private lives of people. as the targets 
of this attack, we have not fared well so far. Lost 
in debates about the excessive sophistication of 
our lifestyles after 30 years of (apparent) peace,42 
we were caught unprepared. So far, propelled by 
the SarS syndrome (a deadly pneumonia kill-
ing anyone without notice) and by the conse-
quences of social distancing (bankruptcy due to 
society freezing), most of us have submissively 
witnessed destruction of life which we were used 
to.43, 44 Last but not least, mixed information 
echoed by media seems to rather launch a shad-
ow of doubt on health authority: despite the daily 
news on progresses for a vaccine production, it is 
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dvP, witness the spreading of an internationally 
agreed planning to enhance natural immunity 
pathways as a way to smart control of pathogens 
before the full definition and proof of efficacy of 
vaccines.
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consequences will be hardly foreseeable. For 
example, strict reinforcement of safety measures 
in all medical treatment including day-hospital 
mini-surgery will force the use of disposable 
sheaths, gowns, instruments, increasing costs, 
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novelties of SarS-cov-2 infection
We feel urged to justify our decision to include a proposal for an alternative strategy to arrest the viral diffusion
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